Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Conditions and Results of Operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Information contained in this quarterly report on Form 10-Q contains "forward-looking statements." These forward-looking statements are contained principally in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations," and are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events, including, but not limited to: our future financial performance; the continuation of historical trends; the sufficiency of our resources in funding our operations; the expansion and market acceptance of our product and check-up service lines; our pricing strategies; and our liquidity and capital needs. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include but are not limited to: the risks of limited management, labor, and financial resources; our ability to establish and maintain adequate internal controls; our ability to develop and maintain a market in our securities; and our ability obtain financing, if and when needed, on terms that are acceptable. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

As used in this quarterly report on Form 10-Q, "we", "our", "us" and the "Company" refer to Scientist Home Future Health Limited a Nevada corporation unless the context requires otherwise.

For clarity, Scientist Home Future Health Holding Limited, which was incorporated in the Republic of Marshall Islands, shall be referred to as "Scientist Home Holding" throughout. Scientist Home Future Health Limited, which was incorporated in Hong Kong, shall be referred to as "Scientist Home HK" throughout.

Corporate History

Scientist Home Future Health Limited ("we", "us", "our", or the "Company"), was incorporated on July 3, 2024 in the State of Nevada.

On July 3, 2024, Mr. Chan Siu Hung was appointed as the Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary, and Director of the Company.

On July 3, 2024, we sold 100,000 shares of restricted Common Stock to Mr. Chan Siu Hung, at a price of $0.0001 per share of Common Stock. The total subscription amount paid by Mr. Chan was $10. Mr. Chan serves as our Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

On August 14, 2024, we sold 19,900,000 shares of restricted Common Stock to Mr. Chan Siu Hung, at a price of $0.0001 per share of Common Stock. The total subscription amount paid by Mr. Chan was $1,990.

On September 9, 2024, we sold 1,160,000 shares of restricted Common Stock to Chee Lay Peng, Chan Yan Kit, and Yuen Wai Ling, at a price of $0.002 per share of Common Stock. The total subscription amount paid by each party was $2,320. The total number of shares sold pursuant to the aforementioned transactions was 3,480,000.

On September 26, 2024, the Company acquired 100% of Scientist Home Holding, a company incorporated in the Republic of Marshall Islands on July 8, 2024, from Mr. Chan Siu Hung, who is our Chief Executive Officer and Director. Scientist Home Holding acts as an investment holding vehicle. The total consideration paid pursuant to this acquisition was $1.00. This transaction is classified as a related party transaction.

3

Scientist Home Holding has one wholly owned subsidiary, "Scientist Home HK," which was incorporated in Hong Kong on July 8, 2024, is selling health supplements and topical creams through retail, and provision of physical check-up services.

For the year ended December 31, 2025, the Company issued an aggregated of 236,000 shares of its common stock at $1.5 per share for aggregate gross proceeds of $354,000.

Current Business Operations

Scientist Home Future Health Limited is a Nevada corporation and is not a Chinese operating company.

Scientist Home Future Health Limited operates through its wholly owned subsidiary in Hong Kong, Scientist Home HK, which specializing in the retail trading of health supplements and topical creams, and provision of physical check-up services. Our mission is to develop sustainable rehabilitation solutions, particularly for degenerative diseases, ensuring that our products not only address current symptoms but also support future, long-term health and recovery.

Our operations are primarily focused in Asia, where we have established a presence in Hong Kong. We serve a diverse and growing customer base that values our unique approach to health and wellness. This includes health-conscious individuals seeking natural solutions to maintain their overall wellness, individuals seeking for preventative health care and relief from chronic conditions, elderly populations managing age-related conditions such as arthritis, joint stiffness, and cardiovascular concerns, as well as professionals and athletes experiencing muscle strain, soreness, or minor injuries.

We believe that Scientist Home Future Health Limited is more than just a company - it's a movement towards better health, driven by innovation, tradition, and a deep respect for the healing power of nature. As we continue to expand our reach, our vision remains clear: to be a leading force in the health and wellness industry.

PRC Regulatory Actions and Legal Risks

The PRC government has recently increased oversight over overseas listings, data security, and anti-monopoly enforcement, introducing frameworks such as the PRC Personal Information Protection Law, the Measures for Cybersecurity Review, and CSRC filing requirements. While these regulations create general operational uncertainties for China-based issuers, our Hong Kong-based subsidiary currently operates outside Mainland China without a VIE structure, handles data for fewer than one million users, and is not classified as a critical information infrastructure operator. Consequently, we are not currently required to obtain explicit prior approvals from agencies like the CAC or CSRC for our business operations or offerings.

Transfers of Cash To and From Subsidiaries

Scientist Home Future Health Limited operates through its wholly owned subsidiary in Hong Kong, Scientist Home HK. The Company may rely on dividends or payments to be paid by Scientist Home HK to fund its cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and U.S. investors, to service any debt we may incur and to pay our operating expenses. If Scientist Home HK incurs debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Cash is transferred through our organization in the following manner: (i) funds are transferred from Scientist Home Future Health Limited, our holding company incorporated in Nevada, U.S., to Scientist Home HK in Hong Kong through Scientist Home Holding, our intermediate holding company incorporated in the Republic of Marshall Islands, in the form of capital contributions or loans, as the case may be; and (ii) dividends or other distributions may be paid by Scientist Home HK in Hong Kong to Scientist Home Future Health Limited through Scientist Home Holding.

There is no restriction under the Nevada law on the amount of funding that the Company may provide to our subsidiary in Hong Kong through loans or capital contributions, provided that such provision of funds is in the best interests of, and of commercial benefit to, the Company. The subsidiary in Hong Kong is also permitted under the laws of Hong Kong, to provide funding to the Company, through dividend distributions or payments, without restrictions on the amount of the funds.

There are no restrictions or limitation on our ability to distribute earnings by dividends from our subsidiary in Hong Kong to the Company and our shareholders and U.S. investors, provided that the entity remains solvent after such distribution. According to the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), a company may only make a distribution out of profits available for distribution. Other than the above, we did not adopt or maintain any cash management policies and procedures as of the date of this prospectus.

Under the current practice of the Inland Revenue Department of Hong Kong, no tax is payable in Hong Kong in respect of dividends paid by us.

There are no restrictions or limitations under the laws of Hong Kong imposed on the conversion of Hong Kong dollar into foreign currencies and the remittance of currencies out of Hong Kong, nor is there any restriction on any foreign exchange to transfer cash between the Company and its subsidiary, across borders and to U.S. investors, nor there is any restrictions and limitations to distribute earnings from the subsidiary, to the Company and U.S. investors and amounts owed.

Holding Foreign Companies Accountable Act (HFCAA) Status

Under the HFCA Act, trading prohibitions may apply if the PCAOB cannot inspect our auditor for consecutive years. Our independent auditor, JP Centurion & Partners PLT, is based in Kuala Lumpur, Malaysia, maintains active PCAOB registration, and is not listed under the Mainland China or Hong Kong restriction determinations, though future inspection accessibility remains subject to evolving regulatory conditions.

4

Results of Operations for three and nine months ended September 30, 2026 and 2025

Revenues

For the three months ended September 30, 2026, total revenues increased by $172,380, or 435.3%, to $211,984 compared to $39,604 for the three months ended September 30, 2025. This expansion was driven by a $170,019 increase in retail trading revenue and a new $2,361 contribution from our physical check-up service line. The growth in retail trading revenue was driven by a combination of a base unit price increase enacted at the beginning of 2026 and a corresponding increase in customer volumes.

For the nine months ended September 30, 2026, total revenues increased by $369,063, or 318.2%, to $485,043 compared to $115,980 for the nine months ended September 30, 2025. This cumulative expansion is due to a $358,799 increase in retail product sales to $474,779 and a $10,264 contribution from our new service line. The year-over-year revenue increase across both the three and nine-month periods reflects the full-period compounding effect of our 2026 price increases alongside robust transaction volumes.

Cost of revenues

For the three and nine months ended September 30, 2026, the Company has cost of revenues in the amount of $90,964 and $275,846 respectively. Cost of retail trading revenue was $275,846, while cost of service revenue was $Nil.

For the three and nine months ended September 30, 2025, the Company has cost of revenues in the amount of $23,534 and $66,682 respectively.

The increase in cost of revenues was directly driven by the increased sales volume of our health supplements and topical creams, which required higher aggregate product fulfillment and delivery expenditures. Cost of retail trading revenue was $275,846 for the nine-month period, tracking our sales performance, while the cost of service revenue was $Nil because the primary processing costs for our physical check-up service line are included in localized administrative overhead.

The cost of retail trading revenue was mainly from the products cost and delivery cost. Currently, our product costs are 60% off of the recommended retail price now. Pursuant to the non-exclusive distributor agreement with related party B, related party B shall have the right to revise products price at any time. Price changes shall apply to all purchase orders received after the effective date with the notice, except that any price increase shall be effective immediately upon notice to distributor and apply to those accepted but undelivered orders.

Gross Profit and Margins

For the three months ended September 30, 2026, consolidated gross profit increased by $104,950 to $121,020, representing a total gross margin of 57.1%, compared to a gross profit of $16,070 and a gross margin of 40.6% for the three months ended September 30, 2025.

Our retail trading gross margin for the three months ended September 30, 2026 was 56.6%, representing a significant expansion over the 40.6% retail gross margin in Q3 2025 and the 30.3% margin experienced in the first half of 2026. This margin improvement is directly attributable to the base unit retail price increases implemented at the beginning of 2026, which outpaced our underlying product procurement costs under our distributor arrangement with Related Party B. This structural margin expansion, combined with higher volume, allowed the Company to achieve a positive net income of $8,212 for the third quarter of 2026.

Our service revenue from physical check-ups carries a gross margin of 100% as the underlying operational costs are categorized entirely within localized administrative overhead and general processing expenses.

5

General and Administrative Expenses

For the three and nine months ended September 30, 2026, the Company incurred general and administrative expenses of $112,808 and $400,909 respectively. These were primarily comprised of staff salary, rental fees, consultancy fees, advertising, professional fees, audit fees, and other fees.

For the three and nine months ended September 30, 2025, the Company had general and administrative expenses in the amount of $63,915 and $128,297 respectively. These were primarily comprised of consultancy fees, professional fees, audit fees, IT fees, rental fees, building management fee, company incorporation fees, bank charges, filing fee, printing and stationery.

The increase in general and administrative expenses reflects increased operational scale following the structural expansions implemented throughout fiscal year 2026. This operational change was primarily driven by higher ongoing infrastructure costs, including increased staffing, professional fees, advertising and promotional expenses, and consultant outlays required to manage our expanded commercial footprint.

Net Income/Loss

Our net income for the three months ended September 30, 2026 was $8,212 and net loss for the nine months ended September 30, 2026 was $191,712 respectively.

Our net loss for the three and nine months ended September 30, 2025 were $47,845 and $78,999 respectively.

The comparative nine-month increase in net loss reflects the elevated foundational infrastructure expenses incurred during the first half of fiscal year 2026. The Company experienced higher baseline costs for personnel, specialized consulting, corporate compliance, and retail facility leases prior to the full realization of the corresponding retail revenue volumes.

Liquidity and Capital Resources

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has experienced recurring operating losses, negative cash flows from operations, and has a significant working capital deficit. For the nine months ended September 30, 2026, the Company incurred a net loss of $191,712 and negative cash flows from operating activities of $129,233. As of September 30, 2026, the Company had cash of $13,653, a working capital deficit of $198,046, and an accumulated stockholders' deficit of $78,205. Our current cash balance provides less than one month of operational cash runway based on our regular cash burn requirements.

The Company's operations have been heavily dependent on financial support from related party B, which has provided $264,437 of on-demand funding through September 30, 2026. This balance is interest-free and contractually repayable on demand, which introduces an immediate liquidity strain should the related party request settlement.

These factors, along with the fact that the Company's independent registered public accounting firm expressed substantial doubt about the Company's ability to continue as a going concern in its report on the December 31, 2025 financial statements, raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.

Based on the Company's current operating structure, management estimates its regular operating cash requirements to be a monthly burn rate of approximately $21,300, resulting in a total projected cash outflow and working capital funding gap of $255,600 over the next 12 months to maintain base administrative and operational expenses. To mitigate these conditions and support ongoing operations, management's plans include:

•	Shareholder and external funding: Actively seeking additional capital injections from existing shareholders and external investors through new equity or stock issuances.
•	Cost-control measures: Implementing rigorous operational efficiency plans and targeted cash preservation strategies to strictly monitor and minimize administrative overhead.
•	Continued related party reliance: Drawing on continued working capital advances from related party B as necessary to meet short-term operational obligations.

6

The execution of the equity financing strategy and the continued reliance on funding from Related Party B are subject to market conditions and are outside of management's direct control. The historical financial support from the related party is discretionary, and there is no written or contractually binding financial support agreement in place to secure future funding. Because these plans have not been legally finalized or contractually backed as of the issuance date, it is probable that these plans cannot be effectively implemented to fully mitigate the liquidity risk.

Accordingly, management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Cash used in Operating Activities

Net cash used in operating activities was $129,233 for the nine months ended September 30, 2026. The cash used in operating activities was attributable to the net loss and increase in inventories, contra by increase in advances from a related party, increase in other payables and accrued liabilities, and decrease in deposits and prepayments.

Net cash used in operating activities was $109,474 for the period ended September 30, 2025. The cash used in operating activities was attributable to the net loss, increase in deposits and prepayments and decrease in other payables and accrued liabilities, contra by advances from a related party and decrease in inventories.

7

Cash Used in Investing Activity

For the nine months ended September 30, 2026 and 2025, the Company did not generate nor used any cash in investing activity.

Cash Provided by Financing Activities

Net cash provided by financing activities was $74,334 for the nine months ended September 30, 2026, which was primarily due to advances from a director and advances from a related party.

Net cash provided by financing activities was $368,443 for the period ended September 30, 2025, which was primarily due to issuance of shares, advances from a director and advances from a related party.

Non-cash Related Party Activity

Related Party B directly settled $129,210 and $86,676 of expenses on behalf of the Company for the nine months ended September 30, 2026 and 2025, respectively. This transaction was handled on a non-cash basis and is consequently excluded from the condensed consolidated statement of cash flows. The funding has been recorded as an increase in our non-trade related party obligations, reflecting a non-cash financing facility provided by Related Party B.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders as of September 30, 2026.

Contractual Obligations

As of September 30, 2026, we have two operating lease agreements for two office spaces in Hong Kong with a non-cancellable term of two years from July 1, 2025, to June 30, 2027, and a non-cancellable term of three years from September 16, 2025 to September 15, 2028, with a renewal option for the period from September 16, 2028 to September 15, 2031, respectively. Management has determined that it is reasonably certain to exercise the three-year renewal option due to significant localized leasehold improvements and custom infrastructure installations completed during initial occupancy. Accordingly, the optional renewal period (September 16, 2028, to September 15, 2031) has been included in the lease term, resulting in a total recognized lease term of 72 months.

As of September 30, 2026, the future minimum rental payments under non-cancellable operating leases are due as follows:

Period / Fiscal Year		Future Minimum Payments
Remainder of 2026		$	22,989
2027		$	80,460
2028		$	69,885
2029		$	72,680
2030		$	75,588
2031		$	55,476
Total undiscounted lease obligations		$	377,078

8

Critical Accounting Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Our critical accounting estimates focus on high-judgment areas and sensitivities:

Going Concern Assessment

Evaluation of historical losses and working capital deficits relies heavily on the timing and likelihood of continued discretionary financial backing from Related Party B.

Lease Terms and Extension Options

Determining if a Hong Kong office renewal option is "reasonably certain" under ASC 842 impacts right-of-use assets and lease liabilities.

Allowance for Inventory Obsolescence and Net Realizable Value (NRV)

Shifting demand and product expirations create risks where carrying costs may require sudden write-downs.

Principal-versus-Agent Evaluations (Related-Party Sourcing)

ASC 606 gross revenue presentation hinges on judgments regarding inventory ownership risks and pricing discretion with Related Party B.

9

Recently accounting pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard-setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the adoption of any recently issued standards has had or may have a material impact on its condensed consolidated financial statements or disclosures.

Emerging Growth Company Accounting Election

The Company is an Emerging Growth Company ("EGC") as defined in Section 2(a) of the Securities Act of 1933, as amended, by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Section 107 of the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised financial accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

The Company has elected to use this extended transition period and, as a result, will adopt new or revised accounting standards on the relevant dates on which adoption is required for entities other than public business entities (non-PBEs).

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The new standard requires entities to disclose additional information about certain expenses, such as purchases of inventory, employee compensation, depreciation, intangible asset amortization, as well as selling expenses included in commonly presented expense captions on the income statement. The FASB further clarified the effective date in January 2025 with the issuance of ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted. We are currently evaluating the impact of this ASU on our interim reporting financial statements and disclosures.

In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract ("ASU 2025-07"). ASU 2025-07 adds a new scope exception in ASC Topic 815, Derivatives and Hedging, for certain contracts that are not traded on an exchange and have an underlying that is based on operations or activities specific to one of the parties to the contract. Additionally, the ASU clarifies that when an entity has a right to receive a share-based payment from its customer in exchange for the transfer of goods or services, the share-based payment should be accounted for as noncash consideration within the scope of Topic 606. The ASU is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted. We are currently evaluating the impact of this ASU on our interim reporting financial statements and disclosures.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which intended to improve the navigability of the guidance in Accounting Standards Codification ("ASC") Topic 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides interim financial statements and notes in accordance with GAAP. The ASU also addresses the form and content of such financial statements, adds list to ASC 270 of the interim disclosures required by all other ASC topics, and establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments are not intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements but rather to reflect the effects of the SEC's form and content requirements related to interim reporting. The amendments of this ASU are effective to us for interim reporting periods within annual reporting periods beginning after December 15, 2028, with early adoption permitted. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted. We are currently evaluating the impact of this ASU on our interim reporting financial statements and disclosures.

In December 2025, the FASB issued ASU 2025-12, Codification Improvements. This ASU is intended to enhance the Codification by refining guidance and simplifying its application through technical corrections, helping to enhance consistency and make the standards easier for preparers and users to interpret. The ASU is effective for fiscal years beginning after December 15, 2026, and the interim periods within fiscal years beginning after December 15, 2026. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted. We are currently evaluating the impact of this ASU on our interim reporting financial statements and disclosures.